FOLFIRI regimen
E823219
The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
All labels observed (3)
| Label | Occurrences |
|---|---|
| FOLFIRI | 2 |
| FOLFIRI regimen canonical | 1 |
| folinic acid, fluorouracil, and irinotecan regimen | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9812321 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: FOLFIRI regimen Context triple: [aflibercept, usedWith, FOLFIRI regimen]
-
A.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
B.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: FOLFIRI regimen Target entity description: The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
-
A.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
B.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
C.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
-
D.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
E.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf | chemotherapy regimen ⓘ |
| commonAdverseEffect |
alopecia
ⓘ
anemia ⓘ diarrhea ⓘ fatigue ⓘ mucositis ⓘ nausea ⓘ neutropenia ⓘ thrombocytopenia ⓘ vomiting ⓘ |
| comparedWith | FOLFOX regimen ⓘ |
| contraindicationComponent | irinotecan is contraindicated in severe hepatic impairment ⓘ |
| doseAdjustment | dose reduction may be required in patients with UGT1A1*28 polymorphism for irinotecan ⓘ |
| drugClassComponent |
fluorouracil is an antimetabolite
ⓘ
folinic acid is a reduced folate ⓘ irinotecan is a topoisomerase I inhibitor ⓘ
linked to:
irinotecan
|
| fullName |
folinic acid, fluorouracil, and irinotecan regimen
ⓘ
linked to:
FOLFIRI regimen
|
| hasComponent |
5-fluorouracil
ⓘ
fluorouracil ⓘ folinic acid ⓘ irinotecan ⓘ leucovorin ⓘ |
| indicationContext |
treatment of metastatic colorectal cancer regardless of RAS status when combined with bevacizumab
ⓘ
treatment of metastatic colorectal cancer with RAS wild-type tumors when combined with anti-EGFR therapy ⓘ |
| mechanismComponent |
fluorouracil inhibits thymidylate synthase
ⓘ
folinic acid enhances binding of fluorouracil to thymidylate synthase ⓘ irinotecan inhibits DNA topoisomerase I ⓘ |
| oftenCombinedWith |
aflibercept
ⓘ
bevacizumab ⓘ
linked to:
Avastin
cetuximab ⓘ panitumumab ⓘ ramucirumab ⓘ |
| requiresMonitoring |
complete blood count
ⓘ
liver function tests ⓘ renal function ⓘ |
| routeOfAdministration | intravenous ⓘ |
| seriousAdverseEffect |
febrile neutropenia
ⓘ
gastrointestinal perforation when combined with bevacizumab ⓘ severe diarrhea ⓘ |
| typicalSchedule |
biweekly regimen
ⓘ
repeated every 2 weeks ⓘ |
| usedAs |
first-line therapy for metastatic colorectal cancer
ⓘ
second-line therapy for metastatic colorectal cancer ⓘ |
| usedFor |
advanced colorectal cancer
ⓘ
metastatic colorectal cancer ⓘ recurrent colorectal cancer ⓘ unresectable colorectal cancer ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: FOLFIRI regimen Description of subject: The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: FOLFIRI regimen
linked to: FOLFIRI regimen
linked to: FOLFIRI regimen